Sasso et al. developed lymphangiogenic potentiation of immunotherapy by injecting of VEGF-C-overexpressing and adjuvant-covering killed cancer cells to elicit T cell activation at the injection sites and draining lymph nodes [161]. Here, VEGFC is linked to cancer.